INB-200 by IN8bio for Glioblastoma Multiforme (GBM): Likelihood of Approval

Brought to you by GlobalData

INB-200 is under clinical development by IN8bio and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Glioblastoma Multiforme (GBM) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how INB-200’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

INB-200 overview

ICS-200 is under development for the treatment of glioblastoma multiforme, recurrent glioblastoma multiforme, high-grade glioma and other unspecified solid tumors. It is administered through intracranial route. The therapeutic candidate is developed based on drug resistant immunotherapy (DRI) platform technology and consists of lentiviral vector with genetically modified gamma delta T cells administered along with chemotherapy.

IN8bio overview

IN8bio. is a clinical-stage biopharmaceutical firm focused on the development, marketing, and discovery of gamma-delta T cell therapeutics for cancer therapy. The company is headquartered in United States.

For a complete picture of INB-200’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.

More Data Insights

View More